The coronavirus disease 2019 (COVID‐19) pandemic has resulted in reorganization of healthcare settings affecting the delivery of clinical care to patients with spinal muscular atrophy (SMA). There is a concern that patients with SMA may be at increased risk of manifesting severe symptoms of COVID‐19. Currently approved therapies for SMA improve survival and motor function; however, their delivery requires an increased exposure to the health system and a dedicated healthcare team. In this study, we discuss consensus recommendations pertaining to care of SMA patients during the pandemic. We highlight that SMA treatments should not be perceived as elective. Decisions regarding the delay of treatments should be made with consideration of the potential risks of COVID‐19 exposure and the risk of that delay. We emphasize the importance of collaborative treatment decisions between the patient, family, and healthcare provider, considering any geographic‐ or institution‐specific policies and precautions for COVID‐19.

中文翻译：

---

COVID-19 大流行时代的脊髓性肌萎缩症护理。

2019 年冠状病毒病 (COVID-19) 大流行导致医疗机构重组，影响了向脊髓性肌萎缩症 (SMA) 患者提供临床护理。人们担心 SMA 患者出现 COVID-19 严重症状的风险可能会增加。目前批准的 SMA 疗法可提高生存率和运动功能；然而，他们的交付需要更多地接触卫生系统和专门的医疗团队。在这项研究中，我们讨论了与大流行期间 SMA 患者护理有关的共识建议。我们强调不应将 SMA 治疗视为选择性治疗。关于延迟治疗的决定应考虑 COVID-19 暴露的潜在风险和延迟的风险。